Sales & Marketing

A deep-dive into how pharma companies can apply service operations principles to achieve a greater level of marketing and promotional review committee satisfaction.

Pharma marketers can use their "voice" to increase prominence in advertising.

Michael Wong speaks to Frank Cespedes, a senior lecturer at Harvard Business School, about how biopharma companies should be optimizing their sales and engagement activities for the 2020s.

A look at how UCB is utilizing dynamic targeting via AI to improve overall patient experience.

Brand positioning that targets HCPs is often irrelevant to the payer mindset. Fortunately, market access teams have an option, writes Ed Shankman.

Turning to a next-gen psoriasis treatment to help drive future fortunes.

While COVID-19 has shifted some of the rules, research reveals that practice changes were already afoot for market newcomers.

Uncovering fish oil derivative’s benefit for heart health.

New hope accompanies overdue recognition in sickle cell disease fight.

Addressing the need for fast-acting therapy in treatment-resistant depression.

The world’s most expensive drug put in context.

The key factors behind the sector’s strong surge in new equity fundraisings.

How adoption of the key account management (KAM) model can help drive pharma’s agility in reaching and influencing a more diverse set of healthcare customers and decision-makers.

Multicultural campaigns crafted for diverse populations are insufficiently funded and do not receive the same support as mainstream campaigns, writes Sheila Thorne. While there are plenty of people willing to partner with pharma on these campaigns, will the industry wake up to the changing world ahead?

The right market research insights provide a richer, more-nuanced picture of your customers as people, not just as numbers on a spreadsheet.

While HCPs are turning away from in-person meetings with sales reps amidst the COVID-19 pandemic, there are still strategies for them to keep their pipelines full.

Our latest review of biopharma financial performance reveals solid growth rates in enterprise value and rebounding value-to-sales numbers—proving once again the business imperative of regaining and sustaining shareholder value.

What’s all the mystery about?

How one COVID-sparked model could help usher in needed reset.

Addressing the challenges created by virtual meetings with HCPs, what we have learned about virtual meetings so far, and a look into the future.

Latest reform brouhaha requires a united response focused on real solutions.

Titan Pharmaceuticals' Sunil Bhonsle and Indegene's Jamie Peck talk about their new partnership and how it will move forward in the post-COVID environment.

Embracing expanded digital models key to future ROI.

As the U.S. economy reopens, engagement with healthcare providers and pharma manufacturers will vary significantly from person to person depending on their comfort level. This article provides insight on how engagement could affect product launches.